TRKA (G667S)
Sign in to save this workspaceNTRK1 · Variant type: point · HGVS: p.G667S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 99.3% | 0.7% | 84.21 |
| 2 | Gilteritinib | 99.2% | 0.8% | 88.97 |
| 3 | Sunitinib | 98.8% | 1.2% | 91.73 |
| 4 | Pralsetinib | 98.5% | 1.5% | 93.43 |
| 5 | Entrectinib | 98.3% | 1.7% | 93.69 |
| 6 | Pacritinib | 98.3% | 1.7% | 88.64 |
| 7 | Cabozantinib | 97.7% | 2.3% | 92.73 |
| 8 | Defactinib | 97.5% | 2.5% | 92.68 |
| 9 | Alpelisib | 97.1% | 2.9% | 97.22 |
| 10 | Darovasertib | 95.2% | 4.8% | 96.99 |
| 11 | Tenalisib | 93.6% | 6.4% | 97.98 |
| 12 | Fedratinib | 93.1% | 6.9% | 96.21 |
| 13 | Fostamatinib | 92.5% | 7.5% | 96.74 |
| 14 | Palbociclib | 91.6% | 8.4% | 98.75 |
| 15 | Brigatinib | 88.1% | 11.9% | 82.96 |
| 16 | Rabusertib | 81.0% | 19.1% | 98.74 |
| 17 | Dabrafenib | 74.2% | 25.8% | 94.74 |
| 18 | Canertinib | 71.7% | 28.3% | 96.49 |
| 19 | Futibatinib | 64.1% | 35.9% | 98.48 |
| 20 | Lazertinib | 61.8% | 38.2% | 97.47 |
| 21 | Avapritinib | 61.7% | 38.3% | 97.73 |
| 22 | Lorlatinib | 61.6% | 38.4% | 97.24 |
| 23 | Pazopanib | 52.7% | 47.3% | 97.49 |
| 24 | Selpercatinib | 52.5% | 47.5% | 96.72 |
| 25 | Vandetanib | 52.5% | 47.5% | 95.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 99.3% | 98.9% | +0.4% |
| Gilteritinib | 99.2% | 92.6% | +6.6% |
| Sunitinib | 98.8% | 82.8% | +16.0% |
| Pralsetinib | 98.5% | 98.7% | -0.2% |
| Entrectinib | 98.3% | 99.0% | -0.8% |
| Pacritinib | 98.3% | 89.4% | +8.8% |
| Cabozantinib | 97.7% | 93.6% | +4.1% |
| Defactinib | 97.5% | 80.3% | +17.2% |
| Alpelisib | 97.1% | 97.5% | -0.4% |
| Darovasertib | 95.2% | — | — |
| Tenalisib | 93.6% | 59.0% | +34.6% |
| Fedratinib | 93.1% | 56.2% | +36.9% |
| Fostamatinib | 92.5% | — | — |
| Palbociclib | 91.6% | — | — |
| Brigatinib | 88.1% | — | — |
| Rabusertib | 81.0% | — | — |
| Dabrafenib | 74.2% | — | — |
| Canertinib | 71.7% | — | — |
| Futibatinib | 64.1% | — | — |
| Lazertinib | 61.8% | — | — |
| Avapritinib | 61.7% | — | — |
| Lorlatinib | 61.6% | 63.2% | -1.6% |
| Pazopanib | 52.7% | — | — |
| Selpercatinib | 52.5% | — | — |
| Vandetanib | 52.5% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.0ms